the Lancet – pharmaceutical daily

June 25, 2019 Off

Tricida Announces Publication of Positive Long-Term Phase 3 Clinical Trial Results of Veverimer (TRC101) in The Lancet

TRCA-301E trial is the first, long-term, randomized, multicenter, blinded, placebo-controlled trial to evaluate the treatment of metabolic acidosis in patients…

January 25, 2018 Off

GW conducts study showing the potential of cannabidiol in reducing seizures

By Dino Mustafić

GW Pharmaceuticals and its U.S. subsidiary Greenwich Biosciences, have conducted a study which showed the potential of cannabidiol in reducing…

January 9, 2017 Off

AB Sciences’ masitinib gets new validations

By Dino Mustafić

AB Sciences has more reasons to believe that its protein kinase inhibitor (PKI) masitinib could have FDA’s further clearence, as the results from the pivotal phase 3 study have been published in highly regarded independent general medical journal, The Lancet.